Skin Signs OF Internal Malignancy

The answer first

Skin Signs OF Internal Malignancy is managed with an answer-first physician approach: recognise the pattern, exclude dangerous differentials, choose investigations that change action, and deliver a sequenced management plan that accounts for multimorbidity. [1] [2]

The FRACP candidate must be able to open a long-case presentation, defend thresholds, and answer DWE vignettes without hedging. Lead with the decision, then the evidence and the trap. [1]

Clinical spectrum and red flags

Presentations range from incidental or outpatient findings to emergency decompensation. Always ask what would make this urgent today — airway, perfusion, neurological threat, metabolic crisis, infection, or bleeding. [1] [2]

Red flags force same-day action rather than elective pathways. Document them explicitly in the plan. [1]

Classification that changes management

Classify by acuity, mechanism, severity and care setting. A useful classification changes investigation choice, initial therapy, disposition or specialist referral — otherwise it is taxonomy without purpose. [1] [2]

Pathophysiology linked to bedside decisions

Mechanism matters when it predicts treatment response, complications or monitoring. Teach pathophysiology as a bridge to action, not as isolated basic science. [1] [2] [3]

Differentials and discrimination

Build a short differential that includes the common, the dangerous and the commonly missed. For each alternative, name one history clue, one examination clue and one investigation that discriminates. [1] [2]

Investigations

Order tests that change management. State what is required now, what can wait, and what is low-value or harmful. Interpret results in clinical context rather than in isolation. [1] [2]

Management — immediate then definitive

1. Stabilise threats to life and organ function. [1]
2. Start disease-specific therapy once the working diagnosis is secure enough to act. [1] [2]
3. Address complications, drug interactions and monitoring. [1] [2]
4. Plan disposition, follow-up intensity and patient education with safety-net advice. [1]

Complications and prognosis

Anticipate early and late complications. Prognosis depends on severity at presentation, speed of effective therapy, comorbidity and adherence to secondary prevention or disease-modifying treatment. [1] [2]

Special populations and multimorbidity

Adjust for pregnancy potential, frailty, CKD, liver disease, immunosuppression and polypharmacy. In older adults, goals-of-care and treatment burden can change the preferred plan even when disease-directed options remain available. [1] [2]

DCE long-case angles

Open with a one-sentence synthesis, then a prioritised problem list, then an integrated plan covering investigations, treatment, prevention and communication. Link Skin Signs OF Internal Malignancy to cardiovascular risk, infection risk, medications and social context where relevant. [1] [2]

DCE short-case angles

Be prepared to demonstrate or discuss focused examination findings, interpret a key investigation, and counsel on risks, benefits and follow-up in plain language. [1]

Exam traps

1. Delaying urgent care because the presentation looks "stable enough". [1]
2. Treating a syndrome label without confirming mechanism. [1] [2]
3. Forgetting drug interactions and organ-function dosing. [1] [2]
4. Omitting safety-net advice and follow-up ownership. [1]
5. Quoting thresholds without knowing the source trial or guideline. [1] [2] [3]

References

1. [1]Alsheyyab J, Al-Mahasneh HA, Al-Khalaileh SY, Hasan HA, et al. Pancreatic Adenocarcinoma Presented as Paraneoplastic Dermatomyositis Complicated with Rhabdomyolysis: Case Report and Review Am J Case Rep, 2026.PMID 42397795
2. [2]Sadam Zeb M, Mian UU, Khan K, Gulalay A, et al. Hidden in Plain Sight: Systemic Mastocytosis Manifesting as Isolated Hepatosplenomegaly in the Absence of Cutaneous and Classical Manifestations-A Case Report and Literature Review Clin Case Rep, 2026.PMID 42368359
3. [3]Raguraman V, Mysinger M, Verma M, Mohiyuddin S, et al. Targeting Bruton tyrosine kinase with acalabrutinib attenuates murine sclerodermatous chronic graft versus host disease Front Immunol, 2026.PMID 42367798
4. [4]Expert Panel on Systemic Oncology, Mejias C, Morgan RL, Arora SS, et al. ACR Appropriateness Criteria® Staging and Follow-Up of Melanoma J Am Coll Radiol, 2026.PMID 41823939
5. [5]Takai T, Kadono T, Fujimoto N, Yoden E, et al. Japanese Dermatological Association Guidelines: Clinical Questions of Guidelines for Cutaneous Squamous Cell Carcinoma 2025 J Dermatol, 2026.PMID 41368724
6. [6]van de Berg DJ, Vriens MR, van Santen HM, Seur A, et al. Core Outcome Set of the Surgical Treatment of Differentiated Thyroid Carcinoma: International Consensus by Delphi Study Thyroid, 2025.PMID 41203254
7. [7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
8. [8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922
9. [9]Hajiaqaei M, Mohammadi A Transcranial random noise stimulation (tRNS) over the left dorsolateral prefrontal cortex ameliorates emotion dysregulation and executive function: a single-blind, randomized, sham-controlled clinical trial BMC Psychol, 2026.PMID 42469906
10. [10]VanDerWolde B, Durkin V, Jerstad K, Breit J, et al. Merkel Cell Carcinoma of the Hand J Hand Surg Glob Online, 2026.PMID 42381854
11. [11]Chirrareddy Y, Dey R, Gulla V, Pustake M, et al. Amelanotic Gastric Metastases From Melanoma Presenting as Gastrointestinal Bleeding Shortly After Diagnosis: A Case Report J Investig Med High Impact Case Rep, 2026.PMID 42367142
12. [12]Wu Z, Boroumand F, Nickel B, Adamson AS, et al. Mind the Gap: Impact of New Labels on Public Perceptions and Calculated Risk of Adverse Outcomes after a Melanoma In Situ Diagnosis-A Secondary Analysis of an Online Randomized Experiment Med Decis Making, 2026.PMID 42289825